

# Antibody Drug Conjugates as a New Class of Agents in Treating Ovarian Cancer

Independent Satellite Symposia during The SGO Virtual Annual Meeting on Women's Cancer®

Monday, March 22, 2021

# GOG CONFIDENTIALITY NOTICE

- **This presentation is the property of The GOG Foundation, Inc. (“GOG”) and/or our Sponsors and is strictly confidential. It contains information intended only for the person to whom it is transmitted and is not to be shared with any third party without the prior written consent of the GOG General Counsel.**
- **With receipt of this information, recipient acknowledges and agrees that: (i) this document is not to be distributed; (ii) the recipient will not copy, duplicate, photograph, reproduce, divulge, or distribute this confidential information, in whole or in part, without the express written consent of the GOG General Counsel; and (iii) all of the information herein will be treated as confidential material with no less care than that afforded to its own confidential material.**

# GOG FACULTY DISCLOSURE INFORMATION

## Virtual Symposium, “Antibody Drug Conjugates as a New Class of Agents in Treating Recurrent Ovarian Cancer”

March 22, 2021

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc. as the accredited provider of this activity must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Members of the Program Committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 12 months that may create a conflict of interest.

All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

NAME	NOTHING TO DISCLOSE	DISCLOSURE
<b>Speakers/Moderators</b>		
Robert Coleman, MD		Honorarium: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis, Epsilon, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Gottfried Konecny, MD		Honorarium: GSK Speaker/Adhoc/Consultant: AstraZeneca, Clovis
Bradley Monk, MD		Honorarium: Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, McKesson/US Oncology, Mersana, Novocure, Myriad, Pfizer, Puma, Roche/Genentech, Sorrento, Tesaro/GSK,
David O'Malley, MD		Honorarium: Roche Diagnostics, Watermark, Immunogen, AstraZeneca, Sorrento, Rubius, Elevar, Novartis, Eisai, GSK, Novocure, Genentech, GOG Foundation, Mersana, Seattle Genetics, Ambry, Regeneron, Myriad, GSK/Tesaro, Agenus
Amit Oza, MD	X	
Deb Richardson, MD		Honorarium: AstraZeneca, Deciphera, Genentech, GlaxoSmithKline, Mersana
<b>Planning Committee Members</b>		
Robert Coleman, MD		Honorarium: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis, Epsilon, Genmab/Seattle Genetics, Gradalis, GSK, Immunogen, Janssen, Myriad, Novocure, Oncoquest, Oncologie, Roche/Genentech
Bradley Monk, MD		Honorarium: Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Eisai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, McKesson/US Oncology, Mersana, Novocure, Myriad, Pfizer, Puma, Roche/Genentech, Sorrento, Tesaro/GSK,
Ronald Alvarez, MD		Consultant/Honorarium: Unleash, Papivax Ad Board/Honorarium: Vaccitech, Genentech, AbbVie, EisaiDSMB
Michelle Small	X	

# GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

## Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

## AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **1.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

# AGENDA

- 6:45 pm – 6:50 pm**     **Introduction**  
Robert L. Coleman, MD, US Oncology Research, Houston, Texas, USA
- 6:50 pm – 7:05 pm**     **Targeted Approach using Biomarkers, ADC's The Next Frontier**  
David O'Malley, MD, The Ohio State University Medical Center, Columbus, Ohio, USA
- 7:05 pm – 7:20 pm**     **Folate Receptor Alpha as the Target**  
Amit Oza, MD, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- 7:20 pm – 7:35 pm**     **NaPi2B as the Target**  
Debra Richardson, MD, University of Oklahoma, Oklahoma City, Oklahoma, USA
- 7:35 pm – 7:50 pm**     **Integrating ADCs into the current paradigm**  
Gottfried Konecny, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
- 7:50 pm – 8:00 pm**     **Question/Answer and Wrap**  
Robert L. Coleman, MD, US Oncology Research, Houston, Texas, USA  
All Session Faculty

